treatment group – Page 16 – Communicable Diseases Research

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

COVID-19로 입원한 환자를 대상으로 한 초기 Favipiravir 요법 대 후기 Favipiravir 요법의 전향적 무작위 공개 표지 시험

Clinical Trial

Published on 2020-09-212022-08-08
Journal: Antimicrobial Agents and Chemotherapy [Category] 임상, 진단, 치료제,

A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19

Clinical Trial

Published on 2020-09-212022-10-27
Journal: Antimicrobial Agents and Chemotherapy [Category] COVID-19,

[키워드] 1:1 95% CI 95% confidence interval adjusted hazard ratio adolescents and adult antiviral therapy approved assigned Asymptomatic Avigan clearance clinical conducted Cooperative COVID-19 death Disease progression Endpoint enrolled Favipiravir Fever group hospital IMPROVE in viral Japan late treatment group Multicenter trial occurred Open-label oral broad-spectrum inhibitor Patient performance status primary endpoint Prospective Randomized randomized clinical trial Randomly reduction in regimen Registered registry resolution of symptoms reverse transcription-PCR RNA-dependent RNA polymerase RT-PCR secondary endpoint significantly the patient therapy time to defervescence transient hyperuricemia Treatment treatment group treatment of influenza viral clearance with COVID-19
[DOI] 10.1128/AAC.01897-20 PMC 바로가기 [Article Type] Clinical Trial

Anticoagulation in critically ill patients on mechanical ventilation suffering from COVID-19 disease, The ANTI-CO trial: A structured summary of a study protocol for a randomised controlled trial

COVID-19 질병으로 고통받는 중환자의 기계적 환기에 대한 항응고, The ANTI-CO 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-09-072022-08-13
Journal: Trials [Category] SARS, 임상,

[키워드] 1:1 Abnormalities Administered allergic Anti-Co trial Anticoagulant anticoagulation anticoagulation treatment approval aPTT assumed attending physicians bivalirudin blinded Blinding Clinical improvement Coagulation comparator control group Controlled trial Corporation COVID-19 COVID-19 disease Critically ill patient D-dimer D-dimers dissemination distress dose dropout drug element eligibility eligible exclusion criteria expected experimental group FiO2 for inclusion groups heparin ICU IMPROVE include Inclusion inclusion criteria intervention group intravenously Invasive mechanical ventilation limit Local mechanical ventilation normally distributed number objective on mechanical ventilation outcome P/F P/F ratio PaO2 paO2/fiO2 parallel group parameter participant Patient patients patients with COVID-19 performed Physicians positive power power of 80% Pregnancy Primary outcome protocol randomised randomised controlled trial randomization Randomized receive recruitment Registered registration number respiratory distress Respiratory failure Sample size sample size calculation screened standard treatment status study drug Study protocol subcutaneously subject Taking the mean the patient thrombosis title treated Treatment treatment group Trial registration website
[DOI] 10.1186/s13063-020-04689-1 PMC 바로가기 [Article Type] Letter

The Association of Renin-Angiotensin-Aldosterone System Inhibitors With Outcomes Among a Predominantly Ethnic Minority Patient Population Hospitalized With COVID-19: The Bronx Experience

Internal Medicine

Published on 2020-09-032022-10-31
Journal: Cureus [Category] COVID-19,

[키워드] Absolute lymphocyte count ACE ACE2 receptors ALC Analysis angiotensin II receptor blockers angiotension converting enzymes inhibitors appear ARB association Asthma blocker CAD chronic obstructive conducted congestive heart failure Coronary artery disease coronavirus disease Coronavirus disease 2019 COVID-19 creatinine D-dimer Diabetes Mellitus disease enzyme evaluate experience expression Hospital admission Hospital stay hyperkalemia hypertension incidence indicated inhibitor initial lactate dehydrogenase LDH New York City Older outcome pandemic Patient patient population Population produced pulmonary disease raised receptor Result Retrospective analysis Retrospective study Safe single-center suggested survival rate System the log-rank test therapy Treatment treatment group two groups with COVID-19 worsening
[DOI] 10.7759/cureus.10217 PMC 바로가기 [Article Type] Internal Medicine

The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-09-032022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 48 hours absence Admission all-cause mortality Arm blinded chest imaging clinical commenced Confirmed COVID-19 criteria CRP D-dimer Data analysis database death defined demonstrated determine disease dissemination dose Efficacy element eligible participant enrolled EudraCT Evidence evidence of evidenced facilitate ferritin fibrinogen hospital humanized monoclonal antibody hyper-inflammation IL-6 IL6 immunology independent Infection inflammatory state infused inhibit interleukin-6 intravenous tocilizumab intubation investigators Ireland LDH low dose management Mater moderate to severe multicentre non-invasive ventilation number objective Older open label outcome PaO participant Patient patients with COVID-19 PCR-confirmed COVID-19 performed positive PCR Potential treatment primary endpoint Primary outcome progression protocol pulmonary randomisation randomised randomised controlled trial Randomised trial receive recruited reduced Registered reported Respiratory failure Respiratory function Sample size SARS-CoV2 infection single dose Stage stage 2 Standard Standard dose status Study protocol subject subjects subsequent systemic inflammation target temperature Therapeutics Tocilizumab treatment group Trial ULN university Ventilation website
[DOI] 10.1186/s13063-020-04680-w PMC 바로가기 [Article Type] Letter

Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment

Research article

Published on 2020-09-012022-10-05
Journal: Biomedicine & pharmacotherapy = Biomédecine & phar [Category] 치료법,

[키워드] Administered affected analyzed anti-inflammatory effect antiviral medicine baseline biochemical Blood Blood routine Blood urea nitrogen BUNblood urea nitrogen C-reactive protein CADcoronary artery disease Cardiac troponin I Chest computed tomography Chinese circulating CK-MBcreatine kinase-myocardial band CKcreatine kinase clinical Clinical characteristics clinical symptom Combination combined treatment Computed tomography Coronary artery disease Coronavirus disease 2019 COVID-19 COVID-19coronavirus disease 2019 creatine kinase creatine kinase-myocardial band creatinine CREcreatinine criteria CRPC-reactive protein CTComputed Tomography cTnIcardiac Troponin I demonstrated Diabetes Mellitus discharge disease DMDiabetes mellitus Effect effective Efficacy erythrocyte sedimentation rate ESRerythrocyte sedimentation rate evaluated examined Follow-up global pandemic glutamic-oxaloacetic transaminase glutamic-pyruvic transaminase GOTglutamic-oxaloacetic transaminase GPTglutamic-pyruvic transaminase group HBPhigh blood pressure high blood pressure Hospitalization impairment in both group inflammatory factors interferon Laboratory lactate dehydrogenase LDHlactate dehydrogenase lung Lymphocyte count Mild mitigate moderate Mortality Myoglobin MYOmyoglobin no significant difference novel coronavirus pneumonia Patient PCTProcalcitonin plan procalcitonin proportion pulmonary inflammation Qingfei Paidu decoction QPDQingfei Paidu decoction Randomized controlled trial required Research Result Retrospective study Safe SARS-CoV-2severe acute respiratory syndrome coronavirus-2 SARS-CoVsevere acute respiratory syndrome coronavirus selected severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 Severity Score Symptom TCMTraditional Chinese Medicine therapy TLCtotal lymphocyte count total lymphocyte count Traditional Chinese medicine Treatment treatment group WBCWhite blood cell Western medicine White blood cell White blood cells WMWestern medicine
[DOI] 10.1016/j.biopha.2020.110500 [Article Type] Research article

Chinese herbal medicine for COVID-19: Current evidence with systematic review and meta-analysis

Review article

Published on 2020-09-012022-10-05
Journal: Journal of integrative medicine [Category] SARS, 신약개발,

[키워드] 95% CI 95% confidence interval Adults adverse event adverse events Analysis C-reactive protein Care changes in China Chinese Chinese herbal medicine CHM Cochrane Library collected Computed tomography contagious Continuous control group Controlled trial Course COVID-19 COVID-19 cases criteria CRP current database disease evaluator Evidence Follow-up Google Scholar hazard ratio help IMPROVE Inflammatory inflammatory markers information Infrastructure life-threatening lung CT scan marker Meta-analysis New coronavirus objective Odds ratio outcome Participants Patient peer-reviewed Pneumonia Primary outcome Randomized controlled trial RCT RCTs Result risk risk of bia SARS-CoV-2 screened searched secondary SMD standard care standardized mean difference Study design Symptom systematic review therapy time-to-event analysis Traditional Chinese medicine treat Treatment treatment group Treatment outcome was used were expressed were recorded
[DOI] 10.1016/j.joim.2020.07.008 [Article Type] Review article

Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial

코로나19 환자의 탯줄유래 중간엽줄기세포치료제: 임상 1상

Article

Published on 2020-08-272022-08-13
Journal: Signal Transduction and Targeted Therapy [Category] Fulltext, MERS, 임상, 치료법,

[키워드] aberrant immune response Adverse adverse event adverse events analyzed anti-SARS-CoV-2 antibody assigned both groups Cell Chest computed tomography clinical evaluation Clinical symptoms clinical trial Computed tomography control group coronavirus disease Coronavirus disease 2019 COVID-19 Cytokines death discharged double-blinded Drug development drug treatments enrolled evaluate events facial flushing Fever group Hospitalization hospitalized patient Host-directed therapies Human hypoxia IgG and IgM IgM anti-SARS-CoV-2 antibodies immune responses IMPROVE infusion intravenous intravenous infusion Laboratory parameters Long-term follow-up long-term functional disability long-term treatment Mechanical mechanical ventilation Mesenchymal stem cells MSCs No effective drug non-randomized one patient outcome PaO Patient patients with moderate performed phase Phase 1 pulmonary disease Randomized receiving reduce regimens required Safe serious COVID-19 severe COVID-19 stem cell Stem cell therapy Stem-cell research survivor therapeutic use therapy tissue damage Treatment treatment group Trial Two patient two patients UC-MSC UC-MSCs umbilical Ventilation with COVID-19
[DOI] 10.1038/s41392-020-00286-5 PMC 바로가기 [Article Type] Article

Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells

인간 탯줄 중간엽 줄기세포로 중증 코로나19 치료

Research

Published on 2020-08-182022-08-13
Journal: Stem Cell Research & Therapy [Category] MERS, 임상,

[키워드] 28-day mortality C-reactive protein cell infusion change Chinese clinical Clinical characteristics Clinical improvement clinical symptom Clinical symptoms control group Coronavirus disease-19 (COVID-19) Coronavirus pneumonia COVID-19 Critical critical condition Critical illness CRP determine died effective faster fatigue hematologic Human umbilical cord mesenchymal stem cells IL-6 IL-6 level IL-6 levels incidence infusion interleukin interleukin 6 invasive invasive ventilation Lung inflammation lymphocyte Lymphocyte count measurement mesenchymal stem cell mortality rate MSCs normal range objective oxygen oxygen saturation Patient progression randomly divided reached respiratory Respiratory disease Safe severe COVID-19 Shortness of breath significant difference significantly significantly lower significantly shorter standard treatment stem cell Symptom Therapeutics Treatment treatment group two groups umbilical Umbilical cord weakness
[DOI] 10.1186/s13287-020-01875-5 PMC 바로가기 [Article Type] Research

Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-08-172022-10-29
Journal: Trials [Category] Coronavirus, MERS,

[키워드] 24 hour absolute reduction Administered administration AIFA airway allocation sequence Alpha Anticoagulant anticoagulant therapy Anticoagulant treatment approval Arm Aspergillus assigned assumption average bleeding bleeding event blinded Block randomisation block size BMI Brain Breastfeeding Candida checked childbearing age chronic clinical clinical condition clinically combined use conjunctival contributed corpus Corticosteroid COVID-19 criteria Critical Critically ill cytomegalovirus D-dimer level death defined Delay detect diagnostic discharge dissemination dosage drug dysfunction effective element eligible patient enoxaparin enrolled EudraCT exclusion criteria expected hematemesis hematoma heparin-induced thrombocytopenia Herpe high risk High-dose history hospital hospital discharge Hypothesis ICU ICU free day ICU Patients impairing Inclusion inclusion criteria indicated Infection initial Inpatient intensive care unit interval Intervention Intra-articular intramuscular intravenously invasive Invasive mechanical ventilation investigator Italian limit LMWH low molecular weight low-molecular weight heparin macroscopic major bleeding mechanical ventilation medical intervention Methylprednisolone Mortality mortality rate Myocardial Non-invasive non-invasive ventilation number objective occur ophthalmic organ dysfunction PaO parallel group participant Patient performed Pharyngeal swab Pneumonia positive positive pressure pregnancy test Presence Prophylactic prophylactic dose Prophylaxis protocol random randomisation randomised randomised controlled trial randomization Randomized Randomized controlled trial Randomly Ratio receive recent recruited recruitment Rectal Bleeding red blood cell reduce reducing Registered required risk of death Safety Sample size SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 pneumonia secondary secure severe disease sick significantly sodium status steroid stratified stroke study drug Study protocol subcutaneously surgical syndrome therapeutic therapeutic doses therapy Treatment treatment group unfractionated heparin Venous Thromboembolism ventilated patient Ventilation website Weighting Withdrawal women
[DOI] 10.1186/s13063-020-04645-z PMC 바로가기 [Article Type] Letter